ReviewFrontiers in psychiatry2024
Treatment of antipsychotic-induced hyperprolactinemia: an umbrella review of systematic reviews and meta-analyses.
Review in Frontiers in psychiatry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.
- Pomgulated methionil (LY2140023) in schizophrenia patients: a systematic review and meta-analysis.BMC psychiatry · 2025Pooled it
- Article
- Hyperprolactinemia, hyperandrogenemia, pituitary adenoma, and metabolic disorders in Wiedemann-Steiner syndrome: a case report.BMC endocrine disorders · 2026Article
- Pharmacogenetic Variability and Quality of Life in Adolescent Patients with Schizophrenia: The Impact of Metabolizer Status, Symptom Severity, and Adverse Reactions to Antipsychotic Treatment.Journal of clinical medicine · 2026Article
- Review
- Adjunctive aripiprazole for amisulpride-induced hyperprolactinemia: a preliminary retrospective study showing no reversing effect.Therapeutic advances in psychopharmacology · 2026Article
- Sexual dysfunction associated with antidepressants and antipsychotics: a structured narrative review of mechanisms, assessment, and personalized management.Frontiers in psychiatry · 2026Review
- Sexual reactivation under aripiprazole in schizophrenia: a note for prescribers.Journal of psychiatry & neuroscience : JPN · 2025Article
- Closing the Evidence Gap: Retrospective and Prospective Strategies to Advance Aripiprazole's Potential Benefits in Patients With Cancer.Pharmacology research & perspectives · 2025Article
- Reproductive and Fertility Care of Women with Schizophrenia: A Narrative Review.Healthcare (Basel, Switzerland) · 2025Review
- Article
- Workup of hyperprolactinemia.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2025Article
- Antipsychotics and Change of Weight, Menstrual Cycle, and Metabolic Syndrome Components Among Schizophrenic Women: A 12-Week Longitudinal Prospective Study in Tien Giang, Vietnam.Diabetes, metabolic syndrome and obesity : targets and therapy · 2025Article
- Case Report: Menstrual cycle-related psychosis in bipolar I disorder, remitting with a combined oral contraceptive.Frontiers in psychiatry · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hyperprolactinemia is a common antipsychotic-induced adverse event in psychiatric patients, and the quality of clinical studies investigating the best treatments has varied. Thus, to better summarize the clinical evidence, we performed an umbrella review of overlapping systematic reviews and meta-analyses for the treatment of antipsychotic-induced hyperprolactinemia. Methods: The PubMed, Cochrane Library, PsycINFO, Scopus and EMBASE were searched, and reviews and meta-analyses meeting our inclusion criteria were selected. Relevant data were extracted, and an umbrella review was conducted of all included meta-analyses. The quality of included meta-analyses was assessed by using PRISMA scores and AMSTAR 2 quality evaluation. Finally, the clinical evidence for appropriate treatments was summarized and discussed. Results: Five meta-analyses published between 2013 and 2020 met the requirements for inclusion in this umbrella review. The PRISMA scores of the included meta-analyses ranged from 19.5-26. AMSTAR 2 quality evaluation showed that 2 of the 5 included meta-analyses were of low quality and 3 were of very low quality. The included meta-analyses provide clinical evidence that adding aripiprazole or a dopamine agonist can effectively and safely improve antipsychotic-induced hyperprolactinemia. Two meta-analyses also showed that adjunctive metformin can reduce serum prolactin level, but more clinical trials are needed to confirm this finding. Conclusion: Adjunctive dopamine agonists have been proven to be effective and safe for the treatment of antipsychotic-induced hyperprolactinemia. Among the researched treatments, adding aripiprazole may be the most appropriate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.